Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | MMP2 | P08253 | 2/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7673498 | 0.89 | LMNA (0.59) | HSD17B10LMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4173740 | 0.87 | MEP1B (0.67) | MMP2MMP9RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7668838 | 0.86 | LMNA (0.68) | LMNAMMP2RAB9ANPC1TP53 | |
| SCHEMBL5099330 | 0.86 | MEN1 (0.62) | HSD17B10LMNAMMP9RAB9ANPC1 | |
| SCHEMBL7665894 | 0.85 | LMNA (0.60) | LMNAALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL7580808 | 0.85 | HSD17B10 (0.61) | HSD17B10LMNAMMP2MMP9RAB9A | |
| SCHEMBL7671620 | 0.84 | LMNA (0.59) | LMNAALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL4834530 | 0.84 | LMNA (0.74) | LMNASMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL7673748 | 0.84 | ALDH1A1 (0.74) | LMNASMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL7663470 | 0.84 | LMNA (0.62) | LMNAMMP2SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | claimed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | claimed |
| US-7335686-B2 | Method and composition for treating osteoporosis | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-02-26 | — | — | US | disclosed |
| EP-1678124-A1 | NOVEL MOLECULES TO DEVELOP DRUG FOR THE TREATMENT OF OSTEOPOROSIS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037774-A1 | NOVEL MOLECULES TO DEVELOP DRUG FOR THE TREATMENT OF OSTEOPOROSIS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085537-A1 | Method and composition for treating osteoporosis | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-04-21 | — | — | US | disclosed |
| EP-0757984-B1 | Hydroxamic acid derivatives useful for inhibiting gelatinase | ONO PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-6177466-B1 | Sulfonylamino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| US-6022893-A | PREVENTION AND TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION OR EXCESS ACTIVATION OF GELATINASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-02-08 | — | — | US | disclosed |
| EP-0757984-A1 | Hydroxamic acid derivatives useful for inhibiting gelatinase | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085537-A1 | Method and composition for treating osteoporosis | SOST, CALCR, MSR1 | HSD17B10 2154/4885LMNA 3183/4885MMP2 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.